Praxis Biologics
Executive Summary
Previously announced merger of the Rochester, New York-based vaccine manufacturer with American Cyanamid is effective as of Nov. 14, following vote of approval by Praxis shareholders. . . . Xoma: Berkeley, California-based monoclonal antibody R&D firm completes previously-announced stock swap merger with another monoclonal antibody R&D firm, Ingene, which becomes a wholly owned subsidiary of Xoma. . . .